Article
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
Hepatology (Baltimore, Md.) - 1 Dec 2003
Schiff Eugene R, Lai Ching-Lung, Hadziyannis Stefanos, Neuhaus Peter, Terrault Norah, Colombo Massimo, Tillmann Hans L, Samuel Didier, Zeuzem Stefan, Lilly Leslie, Rendina Maria, Villeneuve Jean-Pierre, Lama Nicole, James Craig, Wulfsohn Michael S, Namini Hamid, Westland Christopher, Xiong Shelly, Choy Gavin S, Van Doren Sally, Fry John, Brosgart Carol L
Abstract excerpt
Three-hundred and twenty-four patients were enrolled in an open-label, multicenter, international study in which pre- and post-liver transplantation (LT) patients with recurrent chronic hepatitis B (CHB) and evidence of lamivudine-resistant HBV were treated with adefovir dipivoxil 10 mg once daily. In the pre- and post-LT cohorts, 128 and 196 patients were treated for a median duration of 18.7 and 56.1 weeks,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.